Skip to main content
OpenTrials
Completed

NCT Number: NCT00073112

A Study of ABT-751 in Patients With Renal Cell Cancer

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Cancer Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

B.C. Vancouver Cancer Agency, Vancouver, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Renal Cell Carcinoma.
  • Recurrent tumor.
  • At least 6 weeks post-nephrectomy.
  • Able to tolerate normal activities of daily living.
  • Adequate bone marrow, kidney, and liver function.

Exclusion criteria

  • Pregnant or breast feeding.
  • Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
  • CNS metastasis.

Treatment and study plan

ABT-751

Drug

Primary outcomes

  1. Objective Response Rate in subjects with RCC

    Time frame: 1 year

Secondary outcomes

  1. Time to Tumor Progression (TTP)

    Time frame: 1 year

  2. Survival

    Time frame: 2 years

  3. Toxicities associated with treatment administration

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Important dates

Study start
2003
Study completion
2006
First posted
Nov 18, 2003
Registry last updated
Nov 29, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.